Literature DB >> 28588679

microRNA-664 enhances proliferation, migration and invasion of lung cancer cells.

Xinhai Zhu1, Sheng Ju1, Feng Yuan1, Guoping Chen1, Yue Shu1, Chuanchuan Li1, Yanhui Xu1, Jing Luo1, Lilong Xia1.   

Abstract

Altered microRNA (miR) expression serves an important role in the development and progression of lung cancer. In the present study, the effect of miR-664 on proliferation, migration and invasion of lung cancer cells was assessed. The proliferation of lung cancer cells with an overexpression of miR-664 was examined via MTT assay. The Caspase-Glo3/7 assay was used to examine the effect of miR-664 on cisplatin-induced apoptosis in lung cancer cells. The migration and invasion of lung cancer cells were assessed by Transwell migration and matrigel invasion assays. Western blot analysis was used to examine the protein expression levels. miR-664 improved the proliferation of lung cancer cells and inhibited cisplatin-induced apoptosis of A549 and A427 cells. Furthermore, altered expression of miR-664 affected migration and invasion of lung cancer cells. In addition, a miR-664 mimic decreased E-cadherin expression and increased vementin and Snail expression in lung cancer cells. Notably, the expression level of protein kinase B in A549 cells was changed following altered expression of miR-664. The results of the present study suggest that miR-664 serves an essential role in tumor development and progression in lung cancer.

Entities:  

Keywords:  apoptosis; metastasis; microRNA; microRNA-664; protein kinase B

Year:  2017        PMID: 28588679      PMCID: PMC5450804          DOI: 10.3892/etm.2017.4433

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  37 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Effect of miR-34b overexpression on the radiosensitivity of non-small cell lung cancer cell lines.

Authors:  Joana Balça-Silva; Sílvia Sousa Neves; Ana Cristina Gonçalves; Ana Margarida Abrantes; João Casalta-Lopes; Maria Filomena Botelho; Ana Bela Sarmento-Ribeiro; Henriqueta Coimbra Silva
Journal:  Anticancer Res       Date:  2012-05       Impact factor: 2.480

Review 3.  MicroRNAs in cancer: biomarkers, functions and therapy.

Authors:  Josie Hayes; Pier Paolo Peruzzi; Sean Lawler
Journal:  Trends Mol Med       Date:  2014-07-12       Impact factor: 11.951

Review 4.  Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer.

Authors:  Claudia Fumarola; Mara A Bonelli; Pier Giorgio Petronini; Roberta R Alfieri
Journal:  Biochem Pharmacol       Date:  2014-05-24       Impact factor: 5.858

5.  Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.

Authors:  F Ciardiello; R Caputo; R Bianco; V Damiano; G Pomatico; S De Placido; A R Bianco; G Tortora
Journal:  Clin Cancer Res       Date:  2000-05       Impact factor: 12.531

6.  Triplet platinum-based combination sequential chemotherapy improves survival outcome and quality of life of advanced non-small cell lung cancer patients.

Authors:  Li-Kun Chen; Ying Liang; Qun-Ying Yang; Fei Xu; Ning-Ning Zhou; Guang-Chuan Xu; Guo-Zhen Liu; Wei-Dong Wei
Journal:  Asian Pac J Cancer Prev       Date:  2012

7.  Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

Authors:  Giuseppe Giaccone; Roy S Herbst; Christian Manegold; Giorgio Scagliotti; Rafael Rosell; Vincent Miller; Ronald B Natale; Joan H Schiller; Joachim Von Pawel; Anna Pluzanska; Ulrich Gatzemeier; John Grous; Judith S Ochs; Steven D Averbuch; Michael K Wolf; Pamela Rennie; Abderrahim Fandi; David H Johnson
Journal:  J Clin Oncol       Date:  2004-03-01       Impact factor: 44.544

Review 8.  The basics of epithelial-mesenchymal transition.

Authors:  Raghu Kalluri; Robert A Weinberg
Journal:  J Clin Invest       Date:  2009-06       Impact factor: 14.808

9.  Suppression of cancer stemness p21-regulating mRNA and microRNA signatures in recurrent ovarian cancer patient samples.

Authors:  Michael F Gallagher; Cynthia Cbb Heffron; Alexandros Laios; Sharon A O'Toole; Brendan Ffrench; Paul C Smyth; Richard J Flavin; Salah A Elbaruni; Cathy D Spillane; Cara M Martin; Orla M Sheils; John J O'Leary
Journal:  J Ovarian Res       Date:  2012-01-19       Impact factor: 4.234

10.  The microRNA-200 family targets multiple non-small cell lung cancer prognostic markers in H1299 cells and BEAS-2B cells.

Authors:  Maricica Pacurari; Joseph B Addison; Naveen Bondalapati; Ying-Wooi Wan; Dajie Luo; Yong Qian; Vincent Castranova; Alexey V Ivanov; Nancy Lan Guo
Journal:  Int J Oncol       Date:  2013-05-27       Impact factor: 5.650

View more
  7 in total

1.  HOXC13 promotes proliferation of lung adenocarcinoma via modulation of CCND1 and CCNE1.

Authors:  Yu Yao; Jing Luo; Qi Sun; Ting Xu; Siqing Sun; Meili Chen; Xin Lin; Qiuping Qian; Yu Zhang; Lin Cao; Po Zhang; Yong Lin
Journal:  Am J Cancer Res       Date:  2017-09-01       Impact factor: 6.166

Review 2.  Narrative review: molecular and genetic profiling of oligometastatic non-small cell lung cancer.

Authors:  Sawsan Rashdan; Puneeth Iyengar; John D Minna; David E Gerber
Journal:  Transl Lung Cancer Res       Date:  2021-07

3.  MicroRNA-584 inhibits cell proliferation and invasion in non-small cell lung cancer by directly targeting MTDH.

Authors:  Yixiang Zhang; Yanjun Wang; Jinguang Wang
Journal:  Exp Ther Med       Date:  2017-12-12       Impact factor: 2.751

4.  Overexpression of miR-664 is associated with poor overall survival and accelerates cell proliferation, migration and invasion in hepatocellular carcinoma.

Authors:  Xianming Wang; Zhengtong Zhou; Tao Zhang; Minghai Wang; Rongwei Xu; Shiyong Qin; Shuguang Zhang
Journal:  Onco Targets Ther       Date:  2019-03-28       Impact factor: 4.147

5.  MicroRNA-664 suppresses the growth of cervical cancer cells via targeting c-Kit.

Authors:  Mingfen Lv; Rongying Ou; Qianwen Zhang; Fan Lin; Xiangyun Li; Keyu Wang; Yunsheng Xu
Journal:  Drug Des Devel Ther       Date:  2019-07-17       Impact factor: 4.162

6.  MicroRNA-664 Targets Insulin Receptor Substrate 1 to Suppress Cell Proliferation and Invasion in Breast Cancer.

Authors:  Liang Wu; Yuefeng Li; Jingye Li; Deliang Ma
Journal:  Oncol Res       Date:  2018-03-01       Impact factor: 5.574

7.  MicroRNA-217 functions as a tumor suppressor in cervical cancer cells through targeting Rho-associated protein kinase 1.

Authors:  Jing Dong; Maoxiu Wang; Donghua Ni; Lixin Zhang; Wen Wang; Xiujuan Cui; Shijie Fu; Shujuan Yao
Journal:  Oncol Lett       Date:  2018-08-20       Impact factor: 2.967

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.